A Multi-center, Non-randomized, Open-label, Parallel Controlled Pharmacokinetic Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Rezvilutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 30 Nov 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 30 Nov 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 02 Nov 2021 Planned End Date changed from 1 Mar 2021 to 1 Jul 2022.